Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Divergent Total Synthesis of (±)-Nobilin D and Structurally Related Bibenzyl Natural Products.

ACS omega·2026
Same author

A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer.

Cell chemical biology·2024
Same author

Intramolecular CH-Hydrogen Bonding During the Dissociation of the Oxaphosphetane Intermediate Facilitates Z/E-Selectivity in Wittig Olefination.

ChemistryOpen·2023
Same author

Cis- and trans-resveratrol have opposite effects on histone serine-ADP-ribosylation and tyrosine induced neurodegeneration.

Nature communications·2022
Same author

Towards resolving the enigma of the dichotomy of resveratrol: cis- and trans-resveratrol have opposite effects on TyrRS-regulated PARP1 activation.

GeroScience·2020
Same author

Dopamine Triggers CTCF-Dependent Morphological and Genomic Remodeling of Astrocytes.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2018
Same journal

Design of Right-Handed D-Sulfonyl-γ-AApeptides with Broad-Spectrum Antimicrobial Activity.

Journal of medicinal chemistry·2026
Same journal

Design and Synthesis of a Novel Covalent Dihydropteridinone Derivative as a Highly Potent and Orally Bioavailable PLK1 Inhibitor for the Treatment of Chronic Myeloid Leukemia.

Journal of medicinal chemistry·2026
Same journal

Discovery of <b>PIPE-791</b>, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders.

Journal of medicinal chemistry·2026
Same journal

Dual Targeting of Nucleotidase-Dependent and -Independent Functions via PROTAC-Mediated CD73 Degradation.

Journal of medicinal chemistry·2026
Same journal

Selective Visualization of ROR1-Positive TNBC of the Mesenchymal-Like Subtype Using Peptide-Based <sup>68</sup>Ga-PET Radiotracers.

Journal of medicinal chemistry·2026
Same journal

Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2.

Journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

Clinically Advancing BDK Inhibitors.

Kukkamudi Sreenivas1, Chintada Nageswara Rao1

  • 1Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia SC-29208, United States.

Journal of Medicinal Chemistry
|January 15, 2025
PubMed
Summary
This summary is machine-generated.

Cardiac disorders link to branched-chain amino acid (BCAA) imbalance. BDK activity impacts BCAA metabolism. A potential BDK inhibitor, PF-07328948, is in clinical trials for cardiovascular disease (CVD) metabolic issues.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Related Experiment Videos

Last Updated: Jun 2, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Metabolic Disorders

Background:

  • Physiopathology of cardiac and related disorders is linked to branched-chain amino acid (BCAA) metabolic imbalance.
  • BCKD kinase (BDK) acts as a negative regulator of the BCAA catabolizing BCKDH complex.
  • Dysregulation of BCAA catabolism is implicated in cardiovascular disease (CVD) pathogenesis.

Purpose of the Study:

  • To investigate the role of BDK in BCAA metabolic dysfunction relevant to cardiac disorders.
  • To evaluate PF-07328948, a potential BDK inhibitor, for its therapeutic potential in metabolic CVD.

Main Methods:

  • The study focuses on the regulatory role of BDK in BCAA metabolism.
  • Preclinical assessment of PF-07328948's drug-like properties.
  • Phase-1 clinical trials are underway to assess PF-07328948 in metabolic CVD.

Main Results:

  • BCAA metabolic imbalance is a key factor in cardiac disorder pathophysiology.
  • BDK is identified as a significant regulator in BCAA catabolic dysfunction.
  • PF-07328948 demonstrates promising drug-like properties for potential therapeutic use.

Conclusions:

  • Targeting BDK may offer a novel therapeutic strategy for metabolic cardiovascular disorders.
  • PF-07328948 represents a clinically relevant BDK inhibitor for CVD treatment.
  • Further clinical investigation is warranted for PF-07328948 in managing metabolic CVD.